Zacks Research Has Pessimistic Outlook of Bruker Q3 Earnings

Bruker Corporation (NASDAQ:BRKR) – Analysts at Zacks Research decreased their Q3 2025 earnings per share estimates for Bruker in a research report issued on Tuesday, October 21st. Zacks Research analyst Team now expects that the medical research company will earn $0.33 per share for the quarter, down from their prior forecast of $0.37. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.85 EPS, FY2025 earnings at $1.97 EPS, Q1 2026 earnings at $0.44 EPS, Q2 2026 earnings at $0.43 EPS, Q3 2026 earnings at $0.53 EPS, Q4 2026 earnings at $0.69 EPS, FY2026 earnings at $2.09 EPS, Q1 2027 earnings at $0.53 EPS, Q2 2027 earnings at $0.59 EPS and FY2027 earnings at $2.46 EPS.

Several other research analysts have also recently weighed in on BRKR. Bank of America decreased their target price on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a “hold” rating in a research report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price objective on shares of Bruker and gave the stock a “buy” rating in a research note on Monday, August 4th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Finally, Citigroup reduced their target price on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $51.00.

Bruker Stock Up 0.4%

BRKR opened at $38.95 on Wednesday. Bruker has a one year low of $28.53 and a one year high of $64.64. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. The stock’s fifty day moving average is $33.84 and its 200-day moving average is $37.01. The company has a market capitalization of $5.91 billion, a PE ratio of 74.91, a P/E/G ratio of 5.46 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $797.40 million during the quarter, compared to analysts’ expectations of $811.17 million. During the same period in the prior year, the firm posted $0.52 EPS. Bruker’s revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a dividend of $0.05 per share. The ex-dividend date was Tuesday, September 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is presently 38.46%.

Insiders Place Their Bets

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the transaction, the director owned 18,016 shares of the company’s stock, valued at approximately $581,016. The trade was a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas increased its position in Bruker by 5.1% during the first quarter. Teacher Retirement System of Texas now owns 29,045 shares of the medical research company’s stock worth $1,212,000 after purchasing an additional 1,422 shares during the last quarter. Amundi grew its stake in shares of Bruker by 373.3% in the 1st quarter. Amundi now owns 42,503 shares of the medical research company’s stock valued at $1,774,000 after buying an additional 33,522 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Bruker by 35.6% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 40,450 shares of the medical research company’s stock worth $1,717,000 after buying an additional 10,624 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its position in shares of Bruker by 71.2% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock valued at $53,298,000 after buying an additional 537,845 shares during the period. Finally, OneDigital Investment Advisors LLC lifted its holdings in Bruker by 38.0% in the first quarter. OneDigital Investment Advisors LLC now owns 5,522 shares of the medical research company’s stock valued at $230,000 after acquiring an additional 1,520 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.